Business
China Resources Sanjiu Medical & Pharmaceutical Co: Revenue and profit declined, but asset growth and Tasly integration drive future potential
China Resources Sanjiu Medical & Pharmaceutical Co: Revenue and profit declined, but asset growth and Tasly integration drive future potential
About this update from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A
Q1 2025 revenue and net profit declined year-over-year, but operating cash flow and total assets grew, driven by the Tasly acquisition. The company faces a challenging market but is leveraging new synergies and focusing on innovation for long-term growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.